hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Yuchanyan is an early Neolithic cave site in Dao County (Daoxian), Hunan, China. The site yielded sherds of ceramic vessels and other artifacts which were dated by analysis of charcoal and bone collagen, giving a date range of 17,500 to 18,300 years old for the pottery. The pottery specimens may be the oldest known examples of pottery. The cave yielded fragmentary remains of 2 or more ceramic vessels, in addition to large amounts of ash, a rich animal bone assemblage, cobble and flake artifacts, bone tools, and shell tools. The artifacts indicate that the cave was a Late Paleolithic foragers' camp. Here we report on the radiocarbon ages of the sediments based on analyses of charcoal and bone collagen. The best-preserved charcoal and bone samples were identified by prescreening in the field and laboratory. The dates range from around 21,000 to 13,800 cal BP. The age of the ancient pottery ranges between 18,300 and 15,430 cal BP. Charcoal and bone collagen samples located above and below one of the fragments produced dates of around 18,000. These ceramic potsherds therefore provide some of the earliest evidence for pottery making in China.
Wolverine is one of the few X-Men characters appearing in nearly every media adaptation of the X-Men franchise, including the 20th Century Fox X-Men films, television, computer and video games. Australian actor Hugh Jackman portrayed Wolverine in the X-Men films, beginning in X-Men (2000). He reprised the role in X2 (2003), X-Men: The Last Stand (2006), X-Men Origins: Wolverine (2009), X-Men: First Class (2011), The Wolverine (2013), X-Men: Days of Future Past (2014), X-Men: Apocalypse (2016), Logan (2017), and Deadpool & Wolverine (2024). Logan received praise from critics, and a nomination for an Academy Award for Best Adapted Screenplay in 2018; it was the first superhero film to be nominated in the category. Deadpool & Wolverine became the highest grossing R-rated film ever made. Wolverine's first animated appearance was in Spider-Man and His Amazing Friends (1981). He has since been featured in a starring capacity in X-Men: The Animated Series (1992–1997), X-Men: Evolution (2000–2003), Wolverine and the X-Men (2009), Marvel Anime: Wolverine and Marvel Anime: X-Men (both 2011), and X-Men '97 (2024–present). The 1992-97 animated series was particularly significant in introducing Wolverine to a mass popular audience. At its peak, in 1994, it was watched by 23 million households weekly, the highest rated show on Fox Kids. Cal Dodd voices the character in X-Men: The Animated Series and its revival X-Men '97; producers suggested that Dodd base his vocal performance on Clint Eastwood.
qPCR is very sensitive (detection of a single mRNA molecule is theoretically possible), but can be expensive depending on the type of reporter used; fluorescently labeled oligonucleotide probes are more expensive than non-specific intercalating fluorescent dyes. For expression profiling, or high-throughput analysis of many genes within a sample, quantitative PCR may be performed for hundreds of genes simultaneously in the case of low-density arrays. A second approach is the hybridization microarray. A single array or "chip" may contain probes to determine transcript levels for every known gene in the genome of one or more organisms. Alternatively, "tag based" technologies like Serial analysis of gene expression (SAGE) and RNA-Seq, which can provide a relative measure of the cellular concentration of different mRNAs, can be used. An advantage of tag-based methods is the "open architecture", allowing for the exact measurement of any transcript, with a known or unknown sequence. Next-generation sequencing (NGS) such as RNA-Seq is another approach, producing vast quantities of sequence data that can be matched to a reference genome. Although NGS is comparatively time-consuming, expensive, and resource-intensive, it can identify single-nucleotide polymorphisms, splice-variants, and novel genes, and can also be used to profile expression in organisms for which little or no sequence information is available.
=== Secreted extracellular condensates === Secreted thyroglobulin colloid and colloid nodules of the thyroid gland Secreted casein 'micelles' of the mammary gland Serum albumin and globulins Secreted lysozyme
Sources: en.wikipedia.org
It is desirable to choose basis functions that reflect the essential feature of incompressible flow – the elements must be divergence-free. While the velocity is the variable of interest, the existence of the stream function or vector potential is necessary by the Helmholtz theorem. Further, to determine fluid flow in the absence of a pressure gradient, one can specify the difference of stream function values across a 2D channel, or the line integral of the tangential component of the vector potential around the channel in 3D, the flow being given by Stokes' theorem. Discussion will be restricted to 2D in the following. We further restrict discussion to continuous Hermite finite elements which have at least first-derivative degrees-of-freedom. With this, one can draw a large number of candidate triangular and rectangular elements from the plate-bending literature. These elements have derivatives as components of the gradient. In 2D, the gradient and curl of a scalar are clearly orthogonal, given by the expressions,
Afghanistan: The Foreign Ministry stipulated that the Assad regime was the "cause of war and instability" and congratulated Tahrir al-Sham. Canada: Prime Minister Justin Trudeau said that the fall of the Assad dictatorship "ends decades of brutal oppression" and said that Canada is monitoring the transition closely. China: The Foreign Ministry stated that it "is closely following the development of the situation in Syria and hopes that Syria returns to stability as soon as possible" and urged all parties to ensure the safety of Chinese citizens in Syria. European Union: EU foreign policy chief Kaja Kallas called the end of Assad's rule a "positive and long-awaited development" and stated she was in close contact with regional ministers. She emphasized that rebuilding Syria would be "long and complicated". France: President Emmanuel Macron commented on social media: "The barbaric state has fallen. At last. I pay tribute to the Syrian people, to their courage, to their patience." He added that France would remain committed to security in the Middle East. Germany: Foreign Minister Annalena Baerbock described the end of the Assad regime as "a big relief for millions of people in Syria" while warning that "the country must not fall into the hands of other radicals". Indonesia: The Ministry of Foreign Affairs reported that the Embassy of Indonesia in Damascus attacked by stray bullets from the Syrian Opposition Forces and causing minor damages to the building on 9 December 2024. No casualties and injured reported from the attack.
In an investigative report published by The Insider news-outlet in 2024, journalist Yuriy Matsarsky stated:"...Captagon produced in underground labs—and in actual Syrian pharmaceutical facilities—is distributed to the fighters of Bashar Assad's army. Interestingly, however, the quantities the country produces far exceed its own military's demand. ... By some estimates, this business gives Syria more money than its entire legal export, and the regime constantly works to increase its profits, primarily by expanding its market reach. To this end, criminal gangs associated with Damascus or Hezbollah have built distribution networks for Captagon in countries where the drug was not previously popular."
Sources: en.wikipedia.org
Opiates such as morphine have been used for pain relief in the United States since the 1800s, and were used during the American Civil War. Opiates soon became known as a "wonder drug" and were prescribed for a wide array of ailments, even for relatively minor treatments such as cough relief. The first published deaths from opioids start being published in The Lancet in 1892 with death reported from Godfrey's Cordial, an opium-containing syrup. Bayer began marketing heroin commercially in 1898. Beginning around 1920, however, the addictiveness was recognized, and doctors became reluctant to prescribe opiates. Heroin was made an illegal drug with the Anti-Heroin Act of 1924, in which the US Congress banned the sale, importation, or manufacture of heroin. In the 1950s, heroin addiction was still fairly uncommon among average Americans, many of whom saw it as a frightening condition. The fear extended into the 1960s and 1970s, although it became common to hear or read about drugs such as cannabis and psychedelics, which were widely used at rock concerts like Woodstock. Heroin addiction began to make the news around 1970 when rock star Janis Joplin died from an overdose. During and after the Vietnam War, addicted soldiers returned from Vietnam, where heroin was easily bought. Heroin addiction grew within low-income housing projects during the same time period. In 1971, congressmen released an explosive report, The World Heroin Problem, on the growing heroin epidemic among US servicemen in Vietnam, finding that ten to fifteen percent were addicted to heroin.
== Treatment == Gilbert's syndrome is a benign condition that typically requires no medical treatment. The primary approach involves patient education and reassurance about the harmless nature of the syndrome. Episodes of jaundice, when they occur, are usually mild and resolve on their own without intervention. To minimize the frequency of these episodes, individuals are advised to avoid known triggers such as fasting, dehydration, stress, and strenuous physical exertion. Maintaining a healthy lifestyle, including regular meals and adequate hydration, can help manage the condition effectively. If jaundice is significant, phenobarbital may be used.
The explanation of the extraordinary efficiency is the use of mixtures in the synthetic steps. If in a traditional reaction one compound is coupled with one reactant and one new compound is formed. If a mixture of compounds containing n components is coupled with a single reactant the number of new compounds formed in the single coupling is n. The difference between the traditional and the split and pool synthesis is convincingly shown by the number of coupling steps in the traditional and the split and pool synthesis of 3,2 million pentapeptides. Conventional synthesis: 3,200,000x5=16,000,000 coupling steps cca 40,000 years S&P synthesis: 20x5=100 coupling steps cca 5 days It is possible to conduct the conventional synthesis rational way as is shown in the figure. In this case, the number of coupling cycles is: 20+400+8,000+160,000+3,200,000=3,368,420 cca 9,200 years
== Uses == Emoxypine is widely used in Russia, primarily for its anti-oxidant properties claimed by the manufacturer. It purportedly exercises anxiolytic, anti-stress, anti-alcohol, anticonvulsant, nootropic, neuroprotective and anti-inflammatory action. Emoxypine presumably improves cerebral blood circulation, inhibits thrombocyte aggregation, lowers cholesterol levels, has cardioprotective and antiatherosclerotic action. The compound's in vitro iron chelating property shows potential in the management of neurodegenerative conditions such as Alzheimer's disease (AD), as well as hematologic disorders.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.